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Sleep alterations are among the most important disabling manifestation symptoms of
Major Depression Disorder (MDD). A critical role of sleep importance is also underlined by
the fact that its adjustment has been proposed as an objective marker of clinical remission
in MDD. Repetitive transcranial magnetic stimulation (rTMS) represents a relatively novel
therapeutic tool for the treatment of drug-resistant depression. Nevertheless, besides
clinical evaluation of the mood improvement after rTMS, we have no clear understanding
of what are the neurophysiological correlates of such treatment. One possible marker
underlying the clinical outcome of rTMS in MDD could be cortical changes on wakefulness
and sleep activity. The aim of this open-label study was to evaluate the efficacy of a
sequential bilateral rTMS treatment over the dorsolateral prefrontal cortex (DLPFC) to
improve the mood in MDD patients, and to determine if rTMS can induce changes
on the sleep structure, and if those changes can be used as a surrogate marker of
the clinical state of the patient. Ten drug-resistant depressed patients participated to
ten daily sessions of sequential bilateral rTMS with a low-frequency TMS (1Hz) over
right-DLPFC and a subsequent high-frequency (10Hz) TMS over left-DLPFC. The clinical
and neurophysiological effects induced by rTMS were evaluated, respectively by means
of the Hamilton Depression Rating Scale (HDRS), and by comparing the sleep pattern
modulations and the spatial changes of EEG frequency bands during both NREM and REM
sleep, before and after the real rTMS treatment. The sequential bilateral rTMS treatment
over the DLPFC induced topographical-specific decrease of the alpha activity during REM
sleep over left-DLPFC, which is significantly associated to the clinical outcome. In line with
the notion of a left frontal hypoactivation in MDD patients, the observed local decrease of
alpha activity after rTMS treatment during the REM sleep suggests that alpha frequency
reduction could be considered as a marker of up-regulation of cortical activity induced by
rTMS, as well as a surrogate neurophysiological correlate of the clinical outcome.
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INTRODUCTION
Major depression disorder (MDD) is considered not only a
remarkable affliction for patients but also an economic bur-
den for modern society (Luppa et al., 2007). The World Health
Organization estimates that about 350 million people globally are
affected by depression and that by 2030 it will rank as the largest
contributor to disease. MDD represents a syndrome that encom-
passes many different symptoms which brutally affect several
domains of the patient’s life, with specific disturbances in mood,
cognition and physical status. Among the physical symptoms,
sleep alterations represent one of the most disabling manifesta-
tions of MDD and an early marker of the depression recurrence
onset (Perlis et al., 1997; Baglioni et al., 2011). Insomnia, delayed
sleep onset, non-restorative sleep with frequent awakenings
during the night, and shorten duration of sleep are the most
reported subjective complaints of MDD patients. Besides clin-
ical observation, an altered macro- and micro-architecture of
sleep characterizes the electroencephalographic (EEG) recordings
of those patients (Lustberg and Reynolds, 2000; Armitage, 2007;
Steiger and Kimura, 2010). An increase of rapid-eye-movement
(REM) density, an increase of fast-frequency EEG activity, a
prolongation of the first REM sleep period (Lauer et al., 1991;
Riemann et al., 1994) with a reduction of sleep efficiency, an
increase in REM sleep latency (Reynolds and Kupfer, 1987)
and EEG slow-wave activity during non-REM sleep (NREM)
(Mayers and Baldwin, 2005) represent the main neurophys-
iological correlates underlying subjective sleep complaints in
the MDD.
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Among EEG sleep disturbances, the REM sleep alterations are
considered not only the main feature that characterize the sleep
of depressed patients (Kupfer, 1976) as their adjustment are even
used as biomarkers of disease remission. In that regard, several
studies reported how antidepressant treatments have a clear-cut
and immediate effects on REM sleep (Reynolds and Kupfer, 1987;
Sandor and Shapiro, 1994; Sharpley and Cowen, 1995; Riemann
et al., 2001), in terms of latency increase (Kupfer et al., 1981) and
density decrease (Buysse et al., 1999), whereas the action on non-
REM sleep are quite inconsistent (Sharpley and Cowen, 1995).
Those data support the hypothesis of a specific link between REM
sleep and depression.
Aiming at facing the drug-resistance in MDD, several non-
pharmacological interventions have been proposed, including
brain stimulation techniques [i.e., electroconvulsive therapy
(ECT), deep brain stimulation (DBS)].
In the last decade, due to its ability to stimulate focally
and non-invasively cortical brain areas (George et al., 2013),
repetitive transcranial magnetic stimulation (rTMS) has been
introduced for the treatment of medication refractory depres-
sion. TMS can induce a transient and painless electro-magnetic
field through the skull, allowing the depolarization of the cor-
tical neurons under the stimulated scalp location, and into
connected areas (Li et al., 2010). Specifically, rTMS allows
to modulate the cortical excitability, in a specific frequency-
manner, with changes that persist beyond the duration of rTMS
application. If applied at high frequency (≥5Hz), TMS has
been shown to induce a cortical excitability increase, while
at low frequency (≤1Hz) it induces a cortical excitability
decrease.
Functional neuroimaging studies suggested that the prefrontal
cortex, with its specific involvement in mood regulation, should
be the cortical target of rTMS treatment in depression (Padberg
and George, 2009). A typical abnormality observed in the cortical
activity of major depressed patients is represented by prefrontal
cortex asymmetry, with hypoactivity in the left dorsolateral pre-
frontal cortex (L-DLPFC) and relative hyperactivity of the right
DLPFC (R-DLPCF) (Drevets, 2000; Walter et al., 2007; Grimm
et al., 2008). That characteristical activation pattern has been
shown both by examining resting cerebral glucose metabolism
and blood flow with PET (Drevets et al., 1997; Videbech et al.,
2002) and with EEG (Bruder et al., 1997; Debener et al., 2000;
Allen et al., 2004). In agreement with those findings, several stud-
ies support the hypothesis that rTMS can increase with high
frequencies and dampening with low frequencies the DLPFC
excitability, rebalancing the altered functioning of the L-DLPFC
and R-DLPFC, respectively involved as neurophysiological medi-
ators of positive and negative mood (Silberman andWeingartner,
1986; Davidson, 1992). The clinical efficacy of rTMS for the
treatment of the MDD (George et al., 2013), has been val-
idated utilizing both unilateral (Lisanby et al., 2009; Pallanti
et al., 2010) and bilateral approach, i.e., low frequency right-
sided and high frequency left-sided over DLPFC (Fitzgerald et al.,
2006). The latter is considered more effective for the treatment
of major depression due the potential additive effect of both fre-
quency stimulations, provided sequentially (Blumberger et al.,
2012).
Although the clinical outcome of rTMS in depressed patients is
relatively established, few studies have investigated the EEG effects
of a rTMS treatment in depressed patients, in terms of corti-
cal frequency changes, on wakefulness (Funk and George, 2008;
Valiulis et al., 2012) and sleep activity (Saeki et al., 2012). In a
recent study, Saeki et al. (2012), focusing their attention on slow
wave activity (SWA) and sleep spindle activity, highlighted a local
increase of SWA during NREM sleep and no change in REM sleep
parameters after five sessions of high frequency rTMS to the left
DLPFC.
Considering the role of other frequency bands, specifically
the alpha activity as a cortical hypoactivity marker of depres-
sion syndrome, we hypothesized that the study of sleep changes
induced by rTMS on all frequency bands, could allow to iden-
tify the biomarkers of the clinical remission and to better disclose
the sleep neurophysiological correlates which could contribute to
the improvement in clinical outcome observed in depressed drug
resistant patients.
In the present open-label study, we aimed at verifying three
outcomes. First, we wanted to evaluated the efficacy of a 10-
days sequential bilateral rTMS treatment over the DLPFC to
modulate mood in the MDD drug resistant patients, as assessed
by the Hamilton Depression Rating Scale (HDRS). The second
aspect was to evaluate if it was possible to induce changes on
macro and micro-structure of sleep by means of rTMS, assessed
by scoring EEG sleep recordings. Finally, we aimed at explor-
ing the possible correlation between the clinical outcome and the
neurophysiological changes.
According to these aims, sequential bilateral rTMS to DLPFC
in treatment-resistant depressed patients, with a low-frequency
TMS (1Hz) over R-DLPFC and a subsequent high-frequency
(10Hz) TMS over L-DLPFC was applied. Spatial changes of EEG
frequency bands were investigated by comparing maps not only
of all EEG power bands but also of Hz-by-Hz EEG power values
before and after rTMS treatment, during both NREM and REM
sleep. The choice to investigate the cortical topography of REM
and NREM sleep separately was dictated by the interest to dif-
ferentiate the neuromodulator effects induced by rTMS on these
sleep stages, considering their specific involvement and recipro-
cal relationship in the pathophysiological changes of depression
(Armitage, 2007). Finally, the magnitude of the relative EEG sleep
changes after rTMS was correlated with the changes of HDRS
with the aim to identify if EEG sleep changes can be considered
a biomarker of clinical outcome.
MATERIALS ANDMETHODS
PATIENTS
Ten patients (5 males and 5 females, of mean age 52.8 ± 6.3 years,
range 42–63 years) were included in this study. All of them had
a diagnosis of MDD, formulated by an expert psychiatrist on
the basis of a structured clinical interview for DSM-IV Axis I
(SCID-I) according to the diagnostic and statistical manual of the
American Psychiatric Association (APA. Diagnostic and statistical
manual of mental disorders. 4th—TR ed. Washington, DC: APA
Press; 2000). The MDD patients had no psychiatric comorbidity
according to DSM-IV criteria, history of neurological disorders,
epilepsy or substance abuse and contraindication for TMS (Rossi
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et al., 2009). For none of them the previous clinical outcome
showed any improvement following the pharmacological antide-
pressant treatment. The pharmacological treatments are detailed
in Table 1.
Patients with primary sleep disorders (International
Classification of Sleep Disorders, 2nd Edition- ICSD-2, 2005) as
evaluated by polysomnographic recordings during an adaptation
night in our laboratory, were excluded from the study.
Additional inclusion criteria were: a score ≥17 at the 21 items
HDRS, or clinical improvement ≤50% obtained on the HDRS
obtained and absence of improvement at the Clinical Global
Impression (CGI) during the drug treatment with at least two
classes of antidepressant drugs in standard doses for a period of
at least 2 months. Prior to the inclusion, all patients had had a
period of constant medication for 2 months and continued the
same medication at the enrolment and for the full duration of
the study. Therefore, pharmacological dosages were kept constant
during the treatment. None of the patients received additional
non pharmacological treatments, such as psychotherapy, during
the study.
This study was approved by the CEIOC Ethics Committee of
IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
Prior the beginning of the study and after a complete description
of it, written informed consent was obtained from each patient.
PROCEDURE
None of the patients was familiar with the rTMS procedure. An
open-label experimental design was used in the present study.
Therefore, before the real treatment, each patient was subjected
to a 3 days administration of a sham rTMS treatment applied
over the parietal cortex, to allow their adaptation to the experi-
mental setting (specifically, to the noise of rTMS). The real rTMS
treatment consisted of 10 daily sessions of stimulation (Monday
through Friday), for two weeks. Each subject underwent the
stimulations at the same time each day, in the late afternoon.
Before the real rTMS treatment and the following day the end
of the whole treatment, the clinical symptoms were evaluated
Table 1 | Concomitant pharmacological medications are detailed for
all patients.
Pharmacological treatment Patients (n = 10)
BZD + SNRI 1
BZD + SNRI + Aneuro 3
BZD + SNRI + Tneuro 1
BZD + SNRI + TCA 1
BZD + SNRI + TCA + Aneuro + MS 1
BZD + TCA + MS 1
BZD + SSRI + SARI + Aneuro 1
SSRI + Tneuro 1
BZD, benzodiazepines; Antidepressants: SSRI, selective serotonin reuptake
inhibitors; SNRI, serotonin-noradrenalin reuptake inhibitors; SARI, serotonin2-
antagonists/serotonin reuptake inhibitors; TCA, tricyclic antidepressants;
Antipsychotics: Tneuro, typical neuroleptic; Aneuro, atypical neuroleptic; MS,
mood stabilizer.
by means of the HDRS. An expert psychiatrist blind to the
treatment performed the clinical rating. As reported above, the
pharmacological treatment was kept constant during the rTMS
treatment.
Each patient participated in the study for five nights. The sleep
recordings, carried out in a sound-proof room, were scheduled in
the adaptation night followed by a baseline night (BSL) in corre-
spondence respectively of the second and third session of sham
pre-treatment, and three nights during the real rTMS treatment,
respectively after the first (R1), the ninth (re-adaptation night—
R2) and tenth (final treatment—R3) rTMS session. Before the
sleep recordings, all patients were stimulated 60min before light
off. Time in bed after lights off was ∼7 h.
TRANSCRANIALMAGNETIC STIMULATION
rTMS was delivered by a Magstim Super Rapid Magnetic
Stimulator (50Hz—biphasic, four boosters) with a standard dou-
ble 70-mm coil (Magstim Company Limited, Whitland, UK). We
alternated two coils, in order to allow cooling during the repet-
itive stimulation without interruption. Before starting the rTMS
treatment, the motor threshold (MT) was determined for each
subject, respectively over the left and right motor area, following
international standards (Rossini et al., 1994).
Aiming to align all patients into a balanced baseline state,
a sham rTMS treatment was employed in the 3 days before
real rTMS. For sham treatment, a 25-mm thick plywood shield,
build to appear as an integral part of the apparatus, was inter-
posed between the coil itself and the scalp, separating the two.
Moreover, the ventral surface of the coil, from which the mag-
netic field was delivered, was upside down and the stimulus
intensity was at 110% of MT. In the sham session, 1200 pulses
at 1Hz frequency for 20 s, with an inter-train interval of 10 s,
were delivered over the parietal cortex. The real rTMS treatment
was delivered at 110% of MT on the frontal scalp area overly-
ing the R-DLPFC and L-DLPFC. For the identification of the
stimulated brain areas, the left and right DLPFCs were local-
ized on the basis of a reconstruction of cerebral cortex in the
Talairach coordinate system using the SofTaxic neuronavigation
system (EMS, Bologna, Italy www.softaxic.com). Using this sys-
tem, we marked the stimulation sites over the left and the right
DLPFC, coinciding with Brodmann areas 46. These localiza-
tions were in accordance to previous reports (e.g., Saeki et al.,
2012).
The coil was placed tangentially to the scalp with the handle
pointing backwards and laterally at about a 45◦ angle away from
the midsagittal axis of the patient’ heads and oriented to elicit a
postero-lateral-anteromedial current flow in the brain tissue. The
rTMS was first applied at low frequency over the R-DLPFC and
then at high frequency over the L-DLPFC.
Low frequency rTMS consisted of 60 trains of stimuli at 1Hz
frequency for 20 s with an inter-train interval of 10 s. High fre-
quency rTMS consisted of 60 trains of stimuli at 10Hz frequency
for 2 s, with an inter-train interval of 28 s. An interval of ∼30min
separated the two sessions. Each session lasted ∼30min and the
total number of pulses was the same between the two stimula-
tion paradigms (in total 1200 pulses both for the 1Hz-TMS and
that for the 10Hz-TMS). These parameters are in line with safety
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recommendations for rTMS (Wassermann, 1998; Wassermann
and Lisanby, 2001).
POLYSOMNOGRAPHIC RECORDINGS
A BrainAmp Recorder System (BrainAmp 32 channel,
BrainProducts GmbH, Munich, Germany) was used for
polygraphic recordings. EEG signals were high pass filtered
with a time constant of 0.3 s and low pass filtered at 70Hz, and
digitized at a sampling rate of 250Hz. The nineteen unipolar EEG
derivations of the international 10–20 system (Fp1, Fp2, F7, F8,
F3, F4, Fz, C4, C3, Cz, P3, P4, Pz, T4, T6, T3, T5, O1, O2) were
recorded from scalp electrodes. Additional electrodes were used
as the ground and reference. The ground electrode was placed in
the midfrontal (Fpz) position. The reference electrode was placed
from a left mastoid, while recordings obtained from rightmastoid
electrode was used off-line to re-reference the scalp recordings.
Ten additional unipolar EEG derivations were recorded. One
electrode was positioned exactly over the individual right DLPFC
(R-DLPFC), and other four electrodes were placed around this
point in each orthogonal direction at a distance of 1 cm. The
R-hotspot (R-DLFPC) resulted very close to the F3 electrode of
the 10–20 system. As a denotation, the four orthogonal positions
will be indicated as “anterior to right dorsolateral prefrontal
cortex” (aR-DLPFC), “medial to right DLPFC” (mR-DLPFC),
“posterior to right DLPFC” (pR-DLPFC), and “lateral to right
DLPFC” (lR-DLPFC). The same montage and denotation was
also used for the left dorsolateral prefrontal cortex (L-DLPFC,
aL-DLPFC, mL-DLPFC, pL-DLPFC, and lL-DLPFC). Horizontal
and vertical eye movements were detected by recording the
electro-oculogram (EOG) in order to monitor subject behavior
on-line and reject, off-line, trials with ocular artifacts. The
submental electromyogram was recorded with a time constant of
0.03 s. Bipolar horizontal eye movements were recorded with a
time constant of 1 s. The bipolar horizontal electrooculogram was
recorded from electrodes placed about 1 cm from the medial and
lateral canthi of the dominant eye. Impedance for all electrodes
was kept below 5 k.
DATA ANALYSIS
Clinical data analysis
The effect of the rTMS treatment on the clinical outcome (HDRS)
was assessed by means of an analysis of variance (ANOVA),
in which the clinical data at BSL and at R3 nights were
compared.
Sleep measures
Sleep stages of BSL and R3 nights were visually scored in 20 s
epochs, according to the standard criteria (Rechtschaffen and
Kales, 1968). The following were considered as dependent vari-
ables: (a) stage 1 latency; (b) stage 2 latency; (c) REM latency; (d)
percentage of stage 1; (e) percentage of stage 2; (f) percentage of
REM sleep; (g) wakefulness after sleep onset (WASO), expressed
as the intra-sleep time (min) spent awake; (h) number of awak-
enings (the number of >10 s episodes of WASO); (i) number of
arousals (the number of <10 s episodes of WASO); (j) total sleep
time (TST), defined as the sum of time spent in stage 1, stage
2, SWS, and REM; (k) total bedtime (TBT); (l) sleep efficiency
index (SEI= TST/TBT× 100). The polysomnographic EEGmea-
sures were submitted to one-way repeated measure ANOVAs,
comparing BSL, and R3 nights.
Quantitative analysis of sleep EEG
The polygraphic signals (29 EEG channels, EOG, and electromyo-
graphy) were low pass filtered at 30Hz, analog to digital con-
verted on-line with a sampling rate of 128Hz, and stored on
the disk of a personal computer. Ocular and muscle artifacts
were excluded off-line by visual inspection. We investigated the
0.50–25.00Hz frequency range, computing the power spectra by
a Fast Fourier Transform routine for 4 s periodgrams. Before
conducting the statistical analyses, the data were reduced to the
traditional EEG bands of sleep, by collapsing adjacent 0.25-Hz
bins: delta (0.50–4.75Hz), theta (5.00–7.75Hz), alpha (8.00–
11.75Hz), sigma (12.00–15.75Hz), and beta (15.00–24.75Hz).
The power spectra were calculated separately for the NREM sleep
(stage 2 + 3 + 4) and the REM sleep. These EEG power values
were considered as dependent measures. The values were log-
transformed, color coded, plotted at the corresponding position
on the planar projection of the scalp surface, and interpolated
(biharmonic spline) between electrodes.
The EEG power maps were computed separately for the BSL
and the R3 nights, and separately for NREM and REM sleep.
Then, power values of the BSL vs. R3 nights were compared for
each band and scalp location by means of paired t-tests. Finally,
the statistical maps of the t-value comparisons were color coded
and plotted separately for NREM and REM sleep.
The Bonferroni correction for multiple comparisons was
applied. Considering the mean correlation between the variables
of the NREM sleep (r = 0.49), the alpha level was then adjusted
to ≤0.0039 (t ≥ 3.84). Similarly, considering the mean correla-
tion between the variables of the REM sleep (r = 0.57), the alpha
level was then adjusted to ≤ 0.0059 (t ≥ 3.58).
RESULTS
CLINICAL DATA
The analysis on the HDRS scores revealed a significant improve-
ment of the clinical status as a consequence of the rTMS treatment
[BSL = 22.2, ± 2.15; R3 = 15.7, ± 5.46; F(1, 9) = 14.16; p =
0.0045]. As shown in Figure 1, nine out of ten patients improved
at HDRS after the rTMS treatment, and their mean percentage
decrease was 35.0% (±13%).
POLYSOMNOGRAPHY
Table 2 reports the results of the analyses of variance on
polysomnographic (PSG) variables. The macrostructural vari-
ables of sleep pointed to a lack of significant differences between
baseline and post-treatment nights (R3), with the exception of a
slight reduction of the time spent in WASO (BSL = 76.9min, ±
54.4; R3 = 52.6min, ±31.4). Notably, there was no change in the
measures of latency and of time spent in the REM sleep.
QUANTITATIVE ANALYSIS OF EEG
NREM sleep
Figure 2 shows the EEG activity in the NREM sleep, averaged
over all the 29 scalp locations during baseline and post-treatment
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sleep. Power maps of both nights indicated stable patterns within
different frequency ranges, and the data of maxima and min-
ima exhibited the typical features of power spectra during the
NREM sleep. The delta and alpha bands showed a frontal midline
predominance and minimum values over the temporal regions.
In the theta band, the highest values were at the fronto-central
midline areas, while the sigma band showed a centro-parietal
maxima. These topographical maps were substantially stable in
the different conditions. The lower part of the figure reports the
results of the statistical comparisons, and no significant difference
FIGURE 1 | The effects of rTMS on mood in patients with major
depression. Individual Hamilton Depression Rating Scale (HDRS) score
evaluated at baseline (BSL) and after rTMS treatment (R3). After rTMS
there is a significant decrease of HDRS score that corresponds to a clinical
status improvement.
was highlighted for any frequency band and scalp location as a
consequence of rTMS sessions.
REM sleep
Similarly, Figure 3 shows EEG activity in REM sleep during the
BSL and R3 nights. The same stable patterns within different
frequency bands were roughly maintained in REM sleep, with
the notable exception of the 8–15Hz range. Topographical maps
confirmed a prevalence of the delta band at frontal midline sim-
ilar to NREM sleep, with minimum values over the temporal
regions. In the theta band, the highest values were at the fronto-
central midline areas, while the alpha and sigma bands showed a
centro-parietal maxima. Both the sigma and beta activity showed
minimal values in correspondence of the temporal sites.
The lower part of the figure reports the results of the statistical
comparisons, which pointed to a significant decrease of the alpha
power (t = −3.79; p = 0.0043) over the lL-DLPFC site in the R3
compared to the BSL night.
A further analysis of EEG changes with a 1-Hz frequency
resolution, aimed to refine the significant difference found for
the alpha band, clearly showed that the decrease of EEG activ-
ity during REM sleep, mainly regarded the 9 (9.00–9.75Hz) and
10 (10.00–10.75 Hz) Hz bins. The statistical maps comparing
the BSL and the R3 nights showed that even for those fre-
quency bins the observed differences were significant (Figure 4).
Specifically, we observed a significant decrease in the alpha band
on lL-DLPFC, respectively at 9Hz (t = −4.14; p = 0.0025) and
at 10Hz (t = −4.12; p = 0.0026).
RELATION BETWEEN EEG CHANGES AND CLINICAL IMPROVEMENT
According to the findings of the topographical analyses, the main
questions remains: “Is the EEG difference associated to the extent
clinical improvement?” For this reason, we assessed the cor-
relation between the magnitude of decreased alpha activity in
Table 2 | Means and standard deviations (SD) of the polysomnographic variables, before (BSL) and after rTMS treatment (R3), based on visual
scoring for all patients.
Variables BSL R3 F (1, 9) P
Mean SD Mean SD
Stage 1 latency (min) 32.17 27.27 27.36 29.12 0.63 0.45
Stage 2 latency (min) 35.63 30.23 29.80 31.20 0.61 0.45
REM latency (min) 129.90 21.12 122.50 46.68 0.38 0.55
Stage 1 (%) 17.41 16.74 16.99 14.01 0.02 0.88
Stage 2 (%) 66.76 20.55 64.17 18.69 0.94 0.36
REM (%) 15.83 9.41 18.84 6.37 1.76 0.21
WASO (min) 76.88 54.44 52.62 31.35 4.09 0.07
Awakenings (#) 24.20 13.98 21.30 8.65 0.91 0.36
Arousals (#) 82.80 51.42 85.70 53.16 0.22 0.65
TST (min) 414.40 65.62 420.83 69.55 0.13 0.73
TBT (min) 573.23 148.67 501.97 36.98 2.47 0.15
SEI % (TST/TBT) 75.68 18.55 83.74 12.24 2.08 0.18
The results of one-way repeated measure analyses of variance are also reported. No significant difference is present between BSL and R3, with the exception of a
slight reduction of wakefulness after sleep onset. REM, rapid eye movement; WASO, wake after sleep onset; TST, total sleep time; TBT, total bed time; SEI, sleep
efficiency index.
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FIGURE 2 | Topographic distribution of EEG power during NREM sleep
of the baseline night (BSL) and of the night after the rTMS treatment
(R3). Average values are normalized by total power, color-coded, plotted at
the corresponding position on the planar projection of the scalp surface and
interpolated (biharmonic spline) between electrodes. The maps are based
on the 19 unipolar EEG derivations of the international 10–20 system with
averaged mastoid reference, and on 10 additional derivations, positioned in
both hemispheres respectively over left and right dorsolateral prefrontal
cortex and in each orthogonal direction at a distance of 1 cm from the
hotspot (electrode positions indicated by dots). In the upper part, the first
two rows show the absolute EEG power during NREM sleep of the
baseline night (BSL) of the night after the rTMS treatment (R3). Maps are
plotted for the following EEG bands: delta (0.50–4.75Hz), theta
(5.00–7.75Hz), alpha (8.00–11.75Hz), sigma (12.00–15.75Hz), and beta
(15.00–24.75Hz). To optimize the contrast, each map was scaled separately
between minimal (min) and maximal (max) power values. In the lower part,
the statistical maps (t-values maps) of the comparison between R3 vs. BSL
are illustrated for each frequency band (positive t-values indicate a
prevalence of the first over the second term). Please note that the color
code reports the actual t-values (the two-tailed level of significance of
p = 0.0039, after the Bonferroni correction, corresponds to a t = 3.84).
REM sleep at the lL-DLPFC site and the corresponding clin-
ical improvement (in 9 out 10 patients), as expressed by the
post-treatment minus pre-treatment HDRS scores. As shown in
Figure 5, a significant correlation (r = 0.74), although on a small
sample size, was highlighted with larger decreases of alpha activity
in REM sleep associated to larger clinical improvements.
DISCUSSION
The present study was aimed at evaluating the clinical efficacy of
a sequential bilateral rTMS treatment in patients with treatment-
resistant MDD and to assess the rTMS-induced macro- and
microstructural sleep changes. Keeping in mind the limitations
of our open-label design, we observed that rTMS treatment with
high frequency over L-DLPFC and low frequency over R-DLPFC
was able to induce antidepressant effects. The application of rTMS
induced a significant decrease of HDRS score, a clinical marker
of mood improvement. Despite no changes detected in the sleep
macrostructure after the treatment, a frequency-dependent rTMS
effect was observed on the microstructural REM sleep pattern.
Specifically, the rTMS induced an alpha power decrease in the
REM sleep over the L-DLPFC, that resulted strongly correlated
to the clinical outcome.
FIGURE 3 | Topographic distribution of EEG power during REM sleep of
the baseline night (BSL) and of the night after the rTMS treatment
(R3). Average values are normalized by total power, color-coded, plotted at
the corresponding position on the planar projection of the scalp surface and
interpolated (biharmonic spline) between electrodes. The maps are based
on the 19 unipolar EEG derivations of the international 10–20 system with
averaged mastoid reference, and on 10 additional derivations, positioned in
both hemispheres respectively over left and t right dorsolateral prefrontal
cortex and in each orthogonal direction at a distance of 1 cm from the
hotspot (electrode positions indicated by dots). In the upper part, the first
two rows show the absolute EEG power during REM sleep of the baseline
night (BSL) and of the night after the rTMS treatment (R3). Each columns
reports maps of the EEG power in the delta, theta, alpha, sigma, and beta
frequency ranges. To optimize the contrast, each map was scaled
separately between minimal (min) and maximal (max) power values. In the
lower part, the statistical maps (t-values maps) of the comparison between
R3 vs. BSL are illustrated for each frequency band (positive t-values
indicate a prevalence of the first over the second term). Please note that
the color code reports the actual t-values (the two-tailed level of
significance of p = 0.0059, after the Bonferroni correction, corresponds to a
t = 3.58). Specifically, the alpha power decreased significantly (t = −3.79;
p = 0.0043) during REM sleep at R3 respect to BSL night on lL-DLPFC.
FIGURE 4 | Topographic statistical distribution of the change in alpha
power (8.00–11.75Hz), assessed by comparing (t-tests) R3 and
baseline nights, for the REM sleep. Values are expressed in terms of
t-values: negative t-values indicate a decrease at R3 over the baseline night.
Filled white circles indicate electrodes showing a significant difference. The
analysis of EEG changes with a 1-Hz frequency resolution highlighted an
alpha power decrease on lL-DLPFC both to 9Hz (t = −4.14; p = 0.0025)
and to 10Hz (t = −4.12; p = 0.0026).
The observed clinical improvement was in accordance with
previous studies that demonstrated the antidepressant efficacy of
rTMS (George et al., 2000; Burt et al., 2002; Grunhaus et al.,
2003; Fitzgerald et al., 2009). The inclusion of patients with a
diagnosis of medication-resistant depression, in our study, could
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FIGURE 5 | Changes after rTMS treatment in REM alpha power and
clinical improvement, assessed by Hamilton Depression Rating Scale
(HDRS). After 10 days of treatment, the decrease of REM alpha power
results strongly correlated to the treatment outcome.
have limited the magnitude of the therapeutic response, as those
patients show a lower response rate to antidepressant intervention
compared to non-treatment-resistant patients (Fitzgerald, 2003;
Fregni et al., 2006; Brakemeier et al., 2007; Padberg and George,
2009). Even if the mean HDRS response rate decrease was sta-
tistically significant while not clinically relevant, declining from
very severe and severe depression before the treatment to moder-
ate and mild depression after the treatment, our results should be
interpreted positively as the mean percentage of improvements in
HDRS score is 35% after rTMS in nine out of ten non-responders
patients. To that regard, we hypothesized that the lack of clinical
improvement of the non-responder patient to rTMS treatment
could be due to his older age, considering the inverse relation-
ship between age and antidepressant response (Manes et al., 2001;
Fregni et al., 2006); however the direct assessment of the rela-
tion between older age and cortical atrophy has not been viable
in the current protocol. The impact of atrophy, in fact, increasing
the distance of the coil from the prefrontal cortex (Kozel et al.,
2000) would decrease the strength of the induced electrical cur-
rent and limit the effectiveness of treatment. Probably, a rTMS
dose adjusted to overcome cortical atrophy or a more long TMS
course (Lisanby et al., 2009) could have been more effective for
that patient.
Our clinical results support the notion that the sequen-
tial bilateral rTMS combining high frequency left-side and low
frequency right-side is an effective antidepressant treatment
(Fitzgerald et al., 2006), even though by a point of view of
sleep pattern we did not found any macrostructural correlate
to that outcome. Considering the role of the REM sleep as a
diagnostic and prognostic biological marker of depression, the
absence of changes observed on the sleep macrostructure should
be considered unexpected. Some changes on the REM variables
after the rTMS treatment was expected in the direction of inhi-
bition of REM sleep, manifested by an increase of its latency
and a decrease of its amount. However, those changes are fre-
quently observed in the between-subjects protocols that compare
the data of depressed patients with those of healthy control
subjects (Giles et al., 1993). We hypothesized that with the within-
subjects protocol used in this study, it was unlikely to observe
evident changes in sleep parameters, like the REM sleep latency or
density, that could be well stabilized by depressive disorder, rep-
resenting a “trait” characteristic (Rush et al., 1986; Giles et al.,
1989; Tsuno et al., 2005; Rao and Poland, 2008; Pillai et al.,
2011). Moreover, our results confirm the previous findings point-
ing out how some EEG sleep structural measures remain stable
even after pharmacological (Steiger et al., 1989; Kupfer et al.,
1994; Murck et al., 2003), non-pharmacological antidepressant
treatment (Thase et al., 1998) or combined therapy (Giles et al.,
1993).
Although we did not find any changes in the REMmacrostruc-
tural variables, the main result of the present study regards a
specific modulation of the cortical activity during the REM sleep.
The observed decrease of cortical activity in the alpha band dur-
ing the REM sleep after rTMS treatment could represent a specific
microstructural marker of depression’s remission.
From lesion and neuroimaging studies (Baxter et al., 1989;
Martinot et al., 1990; Henriques andDavidson, 1991; Bench et al.,
1992; Biver et al., 1994), it is well established as major depres-
sion is considered as a hypoactivity syndrome associated with
reduced left prefrontal metabolism and cortical dysfunction, in
terms of cortical activation decrease (Drevets, 2000; for a review
see, Koenigs and Grafman, 2009). Several studies have reported
that a marker of this dysregulation could be identified in the alpha
power increase, given the inverse relationship between EEG alpha
and neural activity, and the consequent role of alpha activity as
an inhibitory oscillatory rhythm (Henriques and Davidson, 1990,
1991; Pollock and Schneider, 1990; Ricardo-Garcell et al., 2009;
Kemp et al., 2010). Even though the lack of a control healthy
group does not allow us to verify if our patients were characterized
by a left hypoactivity syndrome (Lubar et al., 2003; Jaworska et al.,
2012), our results can be explained by that model. Regarding the
alpha power decrease observed during the REM sleep and local-
ized over the left cortex stimulated with high frequency rTMS, we
hypothesized that such rTMS frequency, increasing the cortical
excitability, might act toward normalizing the DLPFC dysreg-
ulation, expressed by the cortical activity modulation observed
during the REM sleep. That result is strongly in line with the
increase of the cortical excitability after the high frequency rTMS
(Fitzgerald et al., 2002; Hallett and Rothwell, 2011). Our results
confirm the previous findings that the decrease of the frontal
hypoactivity, probably in terms of cortical activity’s normaliza-
tion, could represent the underlying mechanism by which not
only antidepressant drugs (Baxter et al., 1989; Mayberg et al.,
2000) but also high frequency TMS fosters improvements in
depressive disorder, as highlighted by the higher cerebral blood
flow values and the cortical excitability increase (George et al.,
1999, 2000; Teneback et al., 1999; Speer et al., 2000; Nahas et al.,
2001; Rossini et al., 2010). We hypothesize that the high frequency
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rTMS, stimulating the underlying cortical region and changing
the activity of the corresponding neural tissue, could determine
an up-regulation of the local activity (Chen, 2000; Fitzgerald
et al., 2002). Specifically, the antidepressant effect of the high
frequency TMS could be the result of a re-activation of hypo-
functional L-DLPFC, in terms of increase of cortical activity, and
the neurophysiological biomarker of this effect could be objec-
tified in the decrease of local alpha activity during REM sleep.
Our result is strongly in line with the recent hypothesis that rTMS
alters and resets cortical oscillators, regulating the intrinsic cere-
bral rhythms and restoring normal brain function (Leuchter et al.,
2013). In particular, the high frequency rTMS could act as an
exogenous input, affecting the cortical components, normaliz-
ing the intrinsic brain activity and ameliorating the depressive
symptoms.
Moreover, the high frequency rTMS could modulate not only
the local neuronal firing rate, depolarizing the excitability of neu-
rons, but could also produce a therapeutic effect through the
modulation of the monoaminergic receptors involved in the REM
sleep. In that regard, an attractive hypothesis to explain both
the antidepressant effects induced by rTMS and the REM sleep
modulations could be identified in the involvement of serotonin-
ergic mechanisms (Cohrs et al., 1998; Ben-Shachar et al., 1999;
Gur et al., 2000; Post and Keck, 2001; Adrien, 2002; Padberg
and George, 2009; Baeken et al., 2011). These mechanisms are
the same that are involved in other pharmacological (Maudhuit
et al., 1997) and non-pharmacological (i.e., total or REM sleep
deprivation) (Prevot et al., 1996) antidepressant interventions.
Regarding the bidirectional relationship between sleep distur-
bance and depression (Riemann et al., 2001; Tsuno et al., 2005)
and even though the connection between sleep modifications and
clinical improvement have not yet been established, two possi-
ble scenarios could be hypothesized to explain our results. In the
first one, the rTMS treatment could have acted modulating the
clinical symptoms and their improvement could causally affect
the EEG sleep topography. In the second one, the rTMS-induced
effects on sleep cortical activity could represent the physiolog-
ical framework, underlying the clinical outcome. Although our
results do not allow us to clearly discriminate whether the alpha
activity change observed during REM sleep after rTMS treatment
was the trigger for the clinical improvement or only an its passive
consequence, we speculate that the topographical sleep change
was causally determined by the clinical improvement induced by
rTMS treatment, representing a neurophysiological correlate of
clinical outcome.
The main neurophysiological results of the present study,
namely an alpha decrease during the REM sleep in the same
frequency range of high frequency rTMS applied in this proto-
col (i.e., 10Hz) allow us to speculate that high frequency rTMS
could act by saturating the local alpha power and producing an
excitability increase functional to remission of the depressive dis-
order. A similar change in the alpha band was observed in REM
sleep after a protocol of sleep deprivation (Roth et al., 1999;
Marzano et al., 2010), supporting such frequency as a quantitative
and distinctive marker of REM sleep. In that regard, we specu-
late that the alpha frequency decrease could represent a biological
marker of the sleep pressure for the REM sleep, as the delta power
represents a well-recognized index of sleep homeostasis for the
NREM sleep (Tononi and Cirelli, 2006).
Another important issue is the topography-specificity of the
alpha change between the stimulated DLPFCs. Even though no
sleep frequency changes were observed over the right stimu-
lated cortex, we speculate that the topographical effect over the
L-DLPFC didn’t exclude a sequential effect of low frequency
rTMS applied over the R-DLPFC cortex, most probably through
trans-synaptic connections (Paus et al., 1997; Nahas et al., 2001).
Probably, the application of low frequency before the high fre-
quency rTMS may have contributed to prime the effects observed
over the left cortex, determining a synergetic effect on the clini-
cal outcome (Fitzgerald et al., 2006) even though no detectable at
cortical level.
Finally, even though our study was focused on all EEG fre-
quency bands, our results are partially in agreement with the only
study in which the sleep electrophysiological effects induced by
rTMS treatment on patients with a major depressive episode were
investigated (Saeki et al., 2012). Regarding NREM sleep, in this
latter study a delta power increase at left DLFPC was observed
after the initial five rTMS sessions, but not after the total 10 rTMS
sessions. In agreement to these authors, also our negative finding
on SWA during NREM sleep after 10 rTMS sessions could be due
to the involvement of homeostatic regulation mechanism. On the
other hand, the discrepancy of results during REM sleep, when
we observed a local decrease of alpha activity, could be due to
their focus on two specific EEG frequency bands (slow wave and
spindle activity), not considering all sleep bands.
Several limitations need to be addressed. The first limitation
was the experimental design. The open-label experimental design
and the lack of a sham comparison group (with subsequent sleep
recordings) doesn’t allow us to thoroughly exclude a placebo
effect in the clinical response of our patients (Miniussi et al.,
2005), though the observed linear relationship between EEG and
HDRS changes suggests a specificity of the relationship.
Moreover, our sample size was relatively small and the patients
were all under pharmacological therapy during rTMS treatment,
making it impossible to evaluate the clinical and neurophysio-
logical effect of rTMS as stand-alone treatment. In that regard,
the non-suspension of the drug treatment could be responsible
for the lack of significantmacrostructural differences, highlighted
both in the REM (in terms of latency and density) and the NREM
sleep. Specifically, it is well known how the REM sleep dura-
tion is reduced by the antidepressant drug action until to its
suppression (Holshoe, 2009), and how the NREM sleep, and in
particular the sigma band and SWA are affected by benzodi-
azepines (e.g., Bastien et al., 2003). Only additional studies with
a wider patient sample and patients pharmacological washing
out, as well as a sham condition may allow a better understand-
ing of the macro- and microstructural effects induced by rTMS
treatment on depressive disorder.
CONCLUSION
Concluding, in line with the theory of the left frontal hypoacti-
vation during the rest in depression, the observed local decrease
of alpha activity after rTMS treatment during the REM sleep
confirms the possibility of identifying that EEG frequency as a
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marker of the cortical activity up-regulation induced by high
frequency rTMS as well as a neurophysiological correlate of clini-
cal outcome, providing also an important information regarding
the underlying neuronal circuit responsible of antidepressant
response. The observed correlation between cortical activity
modulation and clinical response indicate clearly that these
results are not respectively related to a TMS-induced brain acti-
vation independent of the treatment response or to the antide-
pressant response to rTMS but are determined by their causal
and direct relationship. This is the first study, to our knowl-
edge, that combining clinical rTMS-induced effects and neu-
rophysiological evaluation of the EEG sleep changes after a
long-term treatment, allows to delineate not only the behavioral
outcome, but also the involved sleep cortical circuits, showing
that the antidepressant effects of rTMS might be mediated by a
significant sleep influence. We conclude that rTMS, and specif-
ically the high frequency stimulation, can represent a relevant
strategy in the modulation of hypoactivity syndrome, like in
MDD and that the study of the microstructural sleep pattern rep-
resents a potential tool for understanding the neurophysiological
mechanisms of the mood disorders and their possible regula-
tion. Finally, we propose the left frontal alpha frequency of the
REM sleep as a state-dependent marker for depression and its
remission.
ACKNOWLEDGMENTS
The authors are grateful to Mrs Claudia Fracassi and Dr Cornelia
Pirulli for their help in data collection and the Italian Ministry
of Health, Grant RF 05/56 to Cristina Marzano and Ricerca
Corrente, for the financial support.
REFERENCES
Adrien, J. (2002). Neurobiological
bases for the relation between sleep
and depression. Sleep Med. Rev. 6,
341–351.
Allen, J. J., Urry, H. L., Hitt, S. K.,
and Coan, J. A. (2004). The stability
of resting frontal electroencephalo-
graphic asymmetry in depression.
Psychophysiology 41, 269–280. doi:
10.1111/j.1469-8986.2003.00149.x
Armitage, R. (2007). Sleep and cir-
cadian rhythms in mood disor-
ders. Acta Psychiatr. Scand. Suppl.
433, 104–115. doi: 10.1111/j.1600-
0447.2007.00968.x
Baeken, C., De Raedt, R., Bossuyt,
A., Van Hove, C., Mertens, J.,
Dobbeleir, A., et al. (2011). The
impact of HF-rTMS treatment
on serotonin(2A) receptors in
unipolar melancholic depression.
Brain Stimul. 4, 104–111. doi:
10.1016/j.brs.2010.09.002
Baglioni, C., Battagliese, G., Feige,
B., Spiegelhalder, K., Nissen, C.,
Voderholzer, U., et al. (2011).
Insomnia as a predictor of depres-
sion: a meta-analytic evaluation
of longitudinal epidemiological
studies. J. Affect. Disord. 135, 10–19.
doi: 10.1016/j.jad.2011.01.011
Bastien, C. H., LeBlanc, M., Carrier,
J., and Morin, C. M. (2003). Sleep
EEG power spectra, insomnia, and
chronic use of benzodiazepines.
Sleep 26, 313–317.
Baxter, L. R. Jr, Schwartz, J. M., Phelps,
M. E., Mazziotta, J. C., Guze,
B. H., Selin, C. E., et al. (1989).
Reduction of prefrontal cortex
glucose metabolism common to
three types of depression. Arch.
Gen. Psychiatry 46, 243–250. doi:
10.1001/archpsyc.1989.0181003004
9007
Bench, C. J., Friston, K. J., Brown, R. G.,
Scott, L. C., Frackowiak, R. S., and
Dolan, R. J. (1992). The anatomy of
melancholia–focal abnormalities of
cerebral blood flow in major depres-
sion. Psychol. Med. 22, 607–615. doi:
10.1017/S003329170003806X
Ben-Shachar, D., Gazawi, H., Riboyad-
Levin, J., and Klein, E. (1999).
Chronic repetitive transcra-
nial magnetic stimulation alters
beta-adrenergic and 5-HT2
receptor characteristics in rat
brain. Brain Res. 816, 78–83. doi:
10.1016/S0006-8993(98)01119-6
Biver, F., Goldman, S., Delvenne,
V., Luxen, A., De Maertelaer, V.,
Hubain, P., et al. (1994). Frontal
and parietal metabolic distur-
bances in unipolar depression.
Biol. Psychiatry 36, 381–388. doi:
10.1016/0006-3223(94)91213-0
Blumberger, D. M., Tran, L. C.,
Fitzgerald, P. B., Hoy, K. E., and
Daskalakis, Z. J. (2012). A random-
ized double-blind sham-controlled
study of transcranial direct current
stimulation for treatment-resistant
major depression. Front. Psychiatry
3:74. doi: 10.3389/fpsyt.2012.00074
Brakemeier, E. L., Luborzewski, A.,
Danker-Hopfe, H., Kathmann,
N., and Bajbouj, M. (2007).
Positive predictors for antide-
pressive response to prefrontal
repetitive transcranial mag-
netic stimulation (rTMS).
J. Psychiatr. Res. 41, 395–403. doi:
10.1016/j.jpsychires.2006.01.013
Bruder, G. E., Fong, R., Tenke, C. E.,
Leite, P., Towey, J. P., Stewart, J.
E., et al. (1997). Regional brain
asymmetries in major depres-
sion with or without an anxiety
disorder: a quantitative elec-
troencephalographic study. Biol.
Psychiatry 41, 939–948. doi:
10.1016/S0006-3223(96)00260-0
Burt, T., Lisanby, S. H., and Sackeim,
H. A. (2002). Neuropsychiatric
applications of transcranial mag-
netic stimulation: a meta analysis.
Int. J. Neuropsychopharmacol. 5,
73–103. doi: 10.1017/S14611457
02002791
Buysse, D. J., Kupfer, D. J., Cherry,
C., Stapf, D., and Frank, E.
(1999). Effects of prior fluoxe-
tine treatment on EEG sleep in
women with recurrent depres-
sion. Neuropsychopharmacology
21, 258–267. doi: 10.1016/S0893-
133X(99)00025-1
Chen, R. (2000). Studies of human
motor physiology with transcranial
magnetic stimulation. Muscle Nerve
Suppl. 9, S26–S32.
Cohrs, S., Tergau, F., Riech, S., Kastner,
S., Paulus, W., Ziemann, U., et al.
(1998). High-frequency repetitive
transcranial magnetic stimula-
tion delays rapid eye movement
sleep. Neuroreport 9, 3439–3443.
doi: 10.1097/00001756-199810260-
00019
Davidson, R. J. (1992). Anterior cere-
bral asymmetry and the nature
of emotion. Brain Cogn. 20,
125–151. doi: 10.1016/0278-2626
(92)90065-T
Debener, S., Beauducel, A., Nessler,
D., Brocke, B., Heilemann, H.,
and Kayser, J. (2000). Is resting
anterior EEG alpha asymmetry
a trait marker for depression.
Findings for healthy adults and
clinically depressed patients.
Neuropsychobiology 41, 31–37. doi:
10.1159/000026630
Drevets, W. C. (2000). Functional
anatomical abnormalities in limbic
and prefrontal cortical structures in
major depression. Prog. Brain Res.
126, 413–431. doi: 10.1016/S0079-
6123(00)26027-5
Drevets, W. C., Price, J. L., Simpson,
J. R. Jr., Todd, R. D., Reich, T.,
and Vannier, M. (1997). Subgenual
prefrontal cortex abnormalities
in mood disorders. Nature 386,
824–827. doi: 10.1038/386824a0
Fitzgerald, P. (2003). Is it time to
introduce repetitive transcra-
nial magnetic stimulation into
standard clinical practice for the
treatment of depressive disor-
ders. Aust. N.Z. J. Psychiatry 37,
5–11. discussion: 12–14. doi:
10.1046/j.1440-1614.2003.01115.x
Fitzgerald, P. B., Benitez, J., de Castella,
A., Daskalakis, Z. J., Brown, T.
L., and Kulkarni, J. (2006). A
randomized, controlled trial of
sequential bilateral repetitive tran-
scranial magnetic stimulation for
treatment-resistant depression.
Am. J. Psychiatry 163, 88–94. doi:
10.1176/appi.ajp.163.1.88
Fitzgerald, P. B., Brown, T. L., and
Daskalakis, Z. J. (2002). The
application of transcranial mag-
netic stimulation in psychiatry
and neurosciences research. Acta
Psychiatr. Scand. 105, 324–340. doi:
10.1034/j.1600-0447.2002.1r179.x
Fitzgerald, P. B., McQueen, S., Herring,
S., Hoy, K., Segrave, R., Kulkarni,
J., et al. (2009). A study of the
effectiveness of high-frequency
left prefrontal cortex transcra-
nial magnetic stimulation in
major depression in patients who
have not responded to right-
sided stimulation. Psychiatry Res.
169, 12–15. doi: 10.1016/j.psychres.
2008.06.017
Fregni, F., Boggio, P. S., Nitsche, M.
A., Rigonatti, S. P., and Pascual-
Leone, A. (2006). Cognitive effects
of repeated sessions of transcra-
nial direct current stimulation
in patients with depression.
Depress. Anxiety 23, 482–484. doi:
10.1002/da.20201
Funk, A. P., and George, M. S. (2008).
Prefrontal EEG asymmetry as a
potential biomarker of antide-
pressant treatment response with
transcranial magnetic stimula-
tion (TMS): a case series. Clin.
Frontiers in Human Neuroscience www.frontiersin.org August 2013 | Volume 7 | Article 433 | 9
Pellicciari et al. REM changes after rTMS-depression treatment
EEG Neurosci. 39, 125–130. doi:
10.1177/155005940803900306
George, M. S., Nahas, Z., Kozel, F.
A., Goldman, J., Molloy, M., and
Oliver, N. (1999). Improvement
of depression following transcra-
nial magnetic stimulation. Curr.
Psychiatry Rep. 1, 114–124. doi:
10.1007/s11920-999-0020-2
George, M. S., Nahas, Z., Molloy, M.,
Speer, A. M., Oliver, N. C., Li, X.
B., et al. (2000). A controlled trial of
daily left prefrontal cortex TMS for
treating depression. Biol. Psychiatry
48, 962–970. doi: 10.1016/S0006-
3223(00)01048-9
George, M. S., Taylor, J. J., and
Short, E. B. (2013). The expand-
ing evidence base for rTMS
treatment of depression. Curr.
Opin. Psychiatry 26, 13–18. doi:
10.1097/YCO.0b013e32835ab46d
Giles, D. E., Etzel, B. A., Reynolds, C.
F. 3rd., and Kupfer, D. J. (1989).
Stability of polysomnographic
parameters in unipolar depres-
sion: a cross-sectional report.
Biol. Psychiatry 25, 807–810. doi:
10.1016/0006-3223(89)90256-4
Giles, D. E., Jarrett, R. B., Rush, A.
J., Biggs, M. M., and Roffwarg, H.
P. (1993). Prospective assessment
of electroencephalographic sleep
in remitted major depression.
Psychiatry Res. 46, 269–284. doi:
10.1016/0165-1781(93)90095-X
Grimm, S., Beck, J., Schuepbach, D.,
Hell, D., Boesiger, P., Bermpohl, F.,
et al. (2008). Imbalance between
left and right dorsolateral pre-
frontal cortex in major depres-
sion is linked to negative emo-
tional judgment: an fMRI study
in severe major depressive disorder.
Biol. Psychiatry 63, 369–376. doi:
10.1016/j.biopsych.2007.05.033
Grunhaus, L., Schreiber, S., Dolberg,
O. T., Polak, D., and Dannon,
P. N. (2003). A randomized con-
trolled comparison of electrocon-
vulsive therapy and repetitive tran-
scranial magnetic stimulation in
severe and resistant nonpsychotic
major depression. Biol. Psychiatry
53, 324–331. doi: 10.1016/S0006-
3223(02)01499-3
Gur, E., Lerer, B., Dremencov, E.,
and Newman, M. E. (2000).
Chronic repetitive transcranial
magnetic stimulation induces
subsensitivity of presynaptic sero-
tonergic autoreceptor activity in rat
brain. Neuroreport 11, 2925–2929.
doi: 10.1097/00001756-200009110-
00019
Hallett, M., and Rothwell, J. (2011).
Milestones in clinical neurophysiol-
ogy. Mov. Disord. 26, 958–967. doi:
10.1002/mds.23572
Henriques, J. B., and Davidson, R.
J. (1990). Regional brain elec-
trical asymmetries discriminate
between previously depressed
and healthy control subjects.
J. Abnorm. Psychol. 99, 22–31. doi:
10.1037/0021-843X.99.1.22
Henriques, J. B., and Davidson, R. J.
(1991). Left frontal hypoactivation
in depression. J. Abnorm. Psychol.
100, 535–545. doi: 10.1037/0021-
843X.100.4.535
Holshoe, J. M. (2009). Antidepressants
and sleep: a review. Perspect.
Psychiatr. Care 45, 191–197. doi:
10.1111/j.1744-6163.2009.00221.x
Jaworska, N., Blier, P., Fusee, W.,
and Knott, V. (2012). Alpha
Power, alpha asymmetry and
anterior cingulate cortex activity
in depressed males and females.
J. Psychiatr. Res. 46, 1483–1491. doi:
10.1016/j.jpsychires.2012.08.003
Kemp, A. H., Griffiths, K.,
Felmingham, K. L., Shankman,
S. A., Drinkenburg, W., Arns,
M., et al. (2010). Disorder
specificity despite comorbidity:
resting EEG alpha asymmetry in
major depressive disorder and
post-traumatic stress disorder.
Biol. Psychol. 85, 350–354. doi:
10.1016/j.biopsycho.2010.08.001
Koenigs, M., and Grafman, J. (2009).
The functional neuroanatomy
of depression: distinct roles
for ventromedial and dorsolat-
eral prefrontal cortex. Behav.
Brain Res. 201, 239–243. doi:
10.1016/j.bbr.2009.03.004
Kozel, F. A., Nahas, Z., deBrux,
C., Molloy, M., Lorberbaum, J.
P., Bohning, D., et al. (2000).
How coil-cortex distance relates
to age, motor threshold, and
antidepressant response to
repetitive transcranial magnetic
stimulation. J. Neuropsychiatry
Clin. Neurosci. 12, 376–384. doi:
10.1176/appi.neuropsych.12.3.376
Kupfer, D. J. (1976). REM latency: a
psychobiologic marker for primary
depressive disease. Biol. Psychiatry
11, 159–174.
Kupfer, D. J., Ehlers, C. L., Frank,
E., Grochocinski, V. J., McEachran,
A. B., and Buhari, A. (1994).
Persistent effects of antidepressants:
EEG sleep studies in depressed
patients during maintenance treat-
ment. Biol. Psychiatry 35, 781–793.
doi: 10.1016/0006-3223(94)91140-1
Kupfer, D. J., Spiker, D. G., Coble, P. A.,
Neil, J. F., Ulrich, R., and Shaw, D.
H. (1981). Sleep and treatment pre-
diction in endogenous depression.
Am. J. Psychiatry 138, 429–434.
Lauer, C. J., Riemann, D., Wiegand,
M., and Berger, M. (1991). From
early to late adulthood. Changes in
EEG sleep of depressed patients and
healthy volunteers. Biol. Psychiatry
29, 979–993. doi: 10.1016/0006-
3223(91)90355-P
Leuchter, A. F., Cook, I. A., Jin,
Y., and Phillips, B. (2013). The
relationship between brain oscil-
latory activity and therapeutic
effectiveness of transcranial mag-
netic stimulation in the treatment
of major depressive disorder.
Front. Hum. Neurosci. 7:37. doi:
10.3389/fnhum.2013.00037
Li, C., Wang, S., Hirvonen, J., Hsieh,
J., Bai, Y., Hong, C., et al. (2010).
Antidepressant mechanism of
add-on repetitive transcra-
nial magnetic stimulation in
medication-resistant depression
using cerebral glucose metabolism.
J. Affect. Disord. 127, 219–229. doi:
10.1016/j.jad.2010.05.028
Lisanby, S. H., Husain, M. M.,
Rosenquist, P. B., Maixner, D.,
Gutierrez, R., Krystal, A., et al.
(2009). Daily left prefrontal
repetitive transcranial magnetic
stimulation in the acute treatment
of major depression: clinical pre-
dictors of outcome in a multisite,
randomized controlled clinical
trial. Neuropsychopharmacology 34,
522–534. doi: 10.1038/npp.2008.
118
Lubar, J. F., Congedo, M., and Askew,
J. H. (2003). Low-resolution electro-
magnetic tomography (LORETA) of
cerebral activity in chronic depres-
sive disorder. Int. J. Psychophysiol.
49, 175–185. doi: 10.1016/S0167-
8760(03)00115-6
Luppa, M., Heinrich, S., Angermeyer,
M. C., Konig, H. H., and Riedel-
Heller, S. G. (2007). Cost-of-illness
studies of depression: a systematic
review. J. Affect. Disord. 98, 29–43.
doi: 10.1016/j.jad.2006.07.017
Lustberg, L., and Reynolds, C. F.
(2000). Depression and insomnia:
questions of cause and effect.
Sleep Med. Rev. 4, 253–262. doi:
10.1053/smrv.1999.0075
Manes, F., Jorge, R., Morcuende,
M., Yamada, T., Paradiso, S.,
and Robinson, R. G. (2001).
A controlled study of repet-
itive transcranial magnetic
stimulation as a treatment of
depression in the elderly. Int.
Psychogeriatr. 13, 225–231. doi:
10.1017/S1041610201007608
Martinot, J. L., Hardy, P., Feline,
A., Huret, J. D., Mazoyer, B.,
Attar-Levy, D., et al. (1990). Left
prefrontal glucose hypometabolism
in the depressed state: a confir-
mation. Am. J. Psychiatry 147,
1313–1317.
Marzano, C., Ferrara, M., Curcio,
G., and De Gennaro, L. (2010).
The effects of sleep depriva-
tion in humans: topographical
electroencephalogram changes
in non-rapid eye movement
(NREM) sleep versus REM sleep.
J. Sleep Res. 19, 260–268. doi:
10.1111/j.1365-2869.2009.00776.x
Maudhuit, C., Prevot, E., Dangoumau,
L., Martin, P., Hamon, M., and
Adrien, J. (1997). Antidepressant
treatment in helpless rats: effect
on the electrophysiological activity
of raphe dorsalis serotonergic
neurons. Psychopharmacology
(Berl.) 130, 269–275. doi:
10.1007/s002130050239
Mayberg, H. S., Brannan, S. K., Tekell,
J. L., Silva, J. A., Mahurin, R.
K., McGinnis, S., et al. (2000).
Regional metabolic effects of
fluoxetine in major depression:
serial changes and relation-
ship to clinical response. Biol.
Psychiatry 48, 830–843. doi:
10.1016/S0006-3223(00)01036-2
Mayers, A. G., and Baldwin, D.
S. (2005). Antidepressants and
their effect on sleep. Hum.
Psychopharmacol. 20, 533–559.
doi: 10.1002/hup.726
Miniussi, C., Bonato, C., Bignotti,
S., Gazzoli, A., Gennarelli, M.,
Pasqualetti, P., et al. (2005).
Repetitive transcranial magnetic
stimulation (rTMS) at high and low
frequency: an efficacious therapy for
major drug-resistant depression?
Clin. Neurophysiol. 116, 1062–1071.
doi: 10.1016/j.clinph.2005.01.002
Murck, H., Nickel, T., Kunzel, H.,
Antonijevic, I. A., Schill, J.,
Zobel, A., et al. (2003). State
markers of depression in sleep
EEG: dependency on drug
and gender in patients treated
with tianeptine or paroxetine.
Neuropsychopharmacology 28,
348–358. doi: 10.1038/sj.npp.130
0029
Nahas, Z., Teneback, C. C., Kozel, A.,
Speer, A. M., DeBrux, C., Molloy,
M., et al. (2001). Brain effects
of TMS delivered over prefrontal
cortex in depressed adults: role
of stimulation frequency and coil-
cortex distance. J. Neuropsychiatry
Clin. Neurosci. 13, 459–470. doi:
10.1176/appi.neuropsych.13.4.459
Padberg, F., and George, M. S.
(2009). Repetitive transcranial
magnetic stimulation of the
prefrontal cortex in depression.
Exp. Neurol. 219, 2–13. doi:
10.1016/j.expneurol.2009.04.020
Pallanti, S., Bernardi, S., Di Rollo,
A., Antonini, S., and Quercioli, L.
(2010). Unilateral low frequency
Frontiers in Human Neuroscience www.frontiersin.org August 2013 | Volume 7 | Article 433 | 10
Pellicciari et al. REM changes after rTMS-depression treatment
versus sequential bilateral repeti-
tive transcranial magnetic stimula-
tion: is simpler better for treatment
of resistant depression?Neuroscience
167, 323–328.
Paus, T., Jech, R., Thompson, C. J.,
Comeau, R., Peters, T., and Evans,
A. C. (1997). Transcranial magnetic
stimulation during positron emis-
sion tomography: a new method
for studying connectivity of the
human cerebral cortex. J. Neurosci.
17, 3178–3184.
Perlis, M. L., Giles, D. E., Buysse, D. J.,
Thase, M. E., Tu, X., and Kupfer,
D. J. (1997). Which depressive
symptoms are related to which
sleep electroencephalographic
variables? Biol. Psychiatry 42,
904–913.
Pillai, V., Kalmbach, D. A., and
Ciesla, J. A. (2011). A meta-
analysis of electroencephalographic
sleep in depression: evidence
for genetic biomarkers. Biol.
Psychiatry 70, 912–919. doi:
10.1016/j.biopsych.2011.07.016
Pollock, V. E., and Schneider, L.
S. (1990). Quantitative, waking
EEG research on depression.
Biol. Psychiatry 27, 757–780. doi:
10.1016/0006-3223(90)90591-O
Post, A., and Keck, M. E. (2001).
Transcranial magnetic stimulation
as a therapeutic tool in psychi-
atry: what do we know about
the neurobiological mechanisms?
J. Psychiatr. Res. 35, 193–215. doi:
10.1016/S0022-3956(01)00023-1
Prevot, E., Maudhuit, C., Le Poul,
E., Hamon, M., and Adrien, J.
(1996). Sleep deprivation reduces
the citalopram-induced inhibition
of serotoninergic neuronal firing in
the nucleus raphe dorsalis of the
rat. J. Sleep Res. 5, 238–245. doi:
10.1111/j.1365-2869.1996.00238.x
Rao, U., and Poland, R. E. (2008).
Electroencephalographic sleep
and hypothalamic-pituitary-
adrenal changes from episode to
recovery in depressed adolescents.
J. Child Adolesc. Psychopharmacol.
18, 607–613. doi: 10.1089/cap.
2008.034
Rechtschaffen, A., and Kales, A.
(1968). A Manual of Standardized
Terminology, Techniques and Scoring
System for Sleep Stages of Human
Subjects. Los Angeles, CA: UCLA
Brain Information Service.
Reynolds, C. F. 3rd., and Kupfer, D. J.
(1987). Sleep research in affective
illness: state of the art circa 1987.
Sleep 10, 199–215.
Ricardo-Garcell, J., Gonzalez-Olvera,
J. J., Miranda, E., Harmony, T.,
Reyes, E., Almeida, L., et al. (2009).
EEG sources in a group of patients
with major depressive disorders. Int.
J. Psychophysiol. 71, 70–74. doi:
10.1016/j.ijpsycho.2008.07.021
Riemann, D., Berger, M., and
Voderholzer, U. (2001). Sleep
and depression–results from psy-
chobiological studies: an overview.
Biol. Psychol. 57, 67–103. doi:
10.1016/S0301-0511(01)00090-4
Riemann, D., Schnitzler, M., Hohagen,
F., and Berger, M. (1994).
Depression and sleep–the sta-
tus of current research. Fortschr.
Neurol. Psychiatr. 62, 458–478. doi:
10.1055/s-2007-1002303
Rossi, S., Hallett, M., Rossini, P. M.,
Pascual-Leone, A., and Safety of
TMS Consensus Group, (2009).
Safety, ethical considerations, and
application guidelines for the use
of transcranial magnetic stim-
ulation in clinical practice and
research. Clin. Neurophysiol. 120,
2008–2039. doi: 10.1016/j.clinph.
2009.08.016
Rossini, D., Lucca, A., Magri, L.,
Malaguti, A., Smeraldi, E.,
Colombo, C., et al. (2010). A
symptom-specific analysis of the
effect of high-frequency left or
low-frequency right transcranial
magnetic stimulation over the dor-
solateral prefrontal cortex in major
depression. Neuropsychobiology 62,
91–97. doi: 10.1159/000315439
Rossini, P. M., Barker, A. T., Berardelli,
A., Caramia, M. D., Caruso, G.,
Cracco, R. Q., et al. (1994). Non-
invasive electrical and magnetic
stimulation of the brain, spinal
cord and roots: basic principles
and procedures for routine clinical
application. Report of an IFCN
committee. Electroencephalogr.
Clin. Neurophysiol. 91, 79–92. doi:
10.1016/0013-4694(94)90029-9
Roth, C., Achermann, P., and Borbely,
A. A. (1999). Alpha activity in the
human REM sleep EEG: topog-
raphy and effect of REM sleep
deprivation. Clin. Neurophysiol. 110,
632–635. doi: 10.1016/S1388-2457
(98)00060-1
Rush, A. J., Erman, M. K., Giles, D.
E., Schlesser, M. A., Carpenter,
G., Vasavada, N., et al. (1986).
Polysomnographic findings
in recently drug-free and
clinically remitted depressed
patients. Arch. Gen. Psychiatry
43, 878–884. doi: 10.1001/arch-
psyc.1986.01800090068009
Saeki, T., Nakamura, M., Hirai, N.,
Noda, Y., Hayasaka, S., Iwanari,
H., et al. (2012). Localized poten-
tiation of sleep slow-wave activ-
ity induced by prefrontal repetitive
transcranial magnetic stimulation
in patients with a major depressive
episode. Brain Stimul. 6, 390–396.
doi: 10.1016/j.brs.2012.08.004
Sandor, P., and Shapiro, C. M. (1994).
Sleep patterns in depression and
anxiety: theory and pharma-
cological effects. J. Psychosom.
Res. 38(Suppl. 1), 125–139. doi:
10.1016/0022-3999(94)90143-0
Sharpley, A. L., and Cowen, P. J. (1995).
Effect of pharmacologic treatments
on the sleep of depressed patients.
Biol. Psychiatry 37, 85–98. doi:
10.1016/0006-3223(94)00135-P
Silberman, E. K., and Weingartner,
H. (1986). Hemispheric lateraliza-
tion of functions related to emo-
tion. Brain Cogn. 5, 322–353. doi:
10.1016/0278-2626(86)90035-7
Speer, A. M., Kimbrell, T. A.,
Wassermann, E. M., D Repella,
J., Willis, M. W., Herscovitch, P.,
et al. (2000). Opposite effects of
high and low frequency rTMS on
regional brain activity in depressed
patients. Biol. Psychiatry 48,
1133–1141. doi: 10.1016/S0006-
3223(00)01065-9
Steiger, A., and Kimura, M. (2010).
Wake and sleep EEG pro-
vide biomarkers in depression.
J. Psychiatr. Res. 44, 242–252. doi:
10.1016/j.jpsychires.2009.08.013
Steiger, A., von Bardeleben, U., Herth,
T., and Holsboer, F. (1989). Sleep
EEG and nocturnal secretion
of cortisol and growth hor-
mone in male patients with
endogenous depression before
treatment and after recovery.
J. Affect. Disord. 16, 189–195. doi:
10.1016/0165-0327(89)90073-6
Teneback, C. C., Nahas, Z., Speer, A.
M., Molloy, M., Stallings, L. E.,
Spicer, K. M., et al. (1999). Changes
in prefrontal cortex and paralimbic
activity in depression following two
weeks of daily left prefrontal TMS.
J. Neuropsychiatry Clin. Neurosci.
11, 426–435.
Thase, M. E., Howland, R. H., and
Friedman, E. S. (1998). Treating
antidepressant nonresponders
with augmentation strategies: an
overview. J. Clin. Psychiatry 59
(Suppl. 5), 5–12. discussion: 13–15.
Tononi, G., and Cirelli, C. (2006). Sleep
function and synaptic homeosta-
sis. Sleep Med. Rev. 10, 49–62. doi:
10.1016/j.smrv.2005.05.002
Tsuno, N., Besset, A., and Ritchie,
K. (2005). Sleep and depression.
J. Clin. Psychiatry 66, 1254–1269.
doi: 10.4088/JCP.v66n1008
Valiulis, V., Gerulskis, G., Dapsys,
K., Vistartaite, G., Siurkute,
A., and Maciulis, V. (2012).
Electrophysiological differences
between high and low frequency
rTMS protocols in depression
treatment. Acta Neurobiol. Exp.
(Wars) 72, 283–295.
Videbech, P., Ravnkilde, B., Pedersen,
T. H., Hartvig, H., Egander, A.,
Clemmensen, K., et al. (2002).
The Danish PET/depression
project: clinical symptoms
and cerebral blood flow. A
regions-of-interest analysis. Acta
Psychiatr. Scand. 106, 35–44. doi:
10.1034/j.1600-0447.2002.02245.x
Walter, H., Wolf, R. C., Spitzer,
M., and Vasic, N. (2007).
Increased left prefrontal activa-
tion in patients with unipolar
depression: an event-related,
parametric, performance-
controlled fMRI study. J. Affect.
Disord. 101, 175–185. doi:
10.1016/j.jad.2006.11.017
Wassermann, E. M. (1998). Risk and
safety of repetitive transcranial
magnetic stimulation: report and
suggested guidelines from the
international workshop on the
safety of repetitive transcranial
magnetic stimulation, June 5-7,
1996. Electroencephalogr. Clin.
Neurophysiol. 108, 1–16. doi:
10.1016/S0168-5597(97)00096-8
Wassermann, E. M., and Lisanby, S.
H. (2001). Therapeutic application
of repetitive transcranial mag-
netic stimulation: a review. Clin.
Neurophysiol. 112, 1367–1377. doi:
10.1016/S1388-2457(01)00585-5
Conflict of Interest Statement: The
authors declare that the research
was conducted in the absence of any
commercial or financial relationships
that could be construed as a potential
conflict of interest.
Received: 23 May 2013; accepted: 16 July
2013; published online: 02 August 2013.
Citation: Pellicciari MC, Cordone S,
Marzano C, Bignotti S, Gazzoli A,
Miniussi C and De Gennaro L (2013)
Dorsolateral prefrontal transcranial
magnetic stimulation in patients with
major depression locally affects alpha
power of REM sleep. Front. Hum.
Neurosci. 7:433. doi: 10.3389/fnhum.
2013.00433
Copyright © 2013 Pellicciari, Cordone,
Marzano, Bignotti, Gazzoli, Miniussi
and De Gennaro. This is an open-access
article distributed under the terms of the
Creative Commons Attribution License
(CC BY). The use, distribution or repro-
duction in other forums is permitted,
provided the original author(s) or licen-
sor are credited and that the original
publication in this journal is cited, in
accordance with accepted academic prac-
tice. No use, distribution or reproduction
is permitted which does not comply with
these terms.
Frontiers in Human Neuroscience www.frontiersin.org August 2013 | Volume 7 | Article 433 | 11
